Publications by authors named "U Julius"

Neutrophil extracellular traps (NETs) are large structures composed of chromatin, histones and granule-derived proteins released extracellularly by neutrophils. They are generally considered to be a part of the antimicrobial defense strategy, preventing the dissemination of pathogens. However, overproduction of NETs or their ineffective clearance can drive various pathologies, many of which are associated with advanced age and involve uncontrolled inflammation, oxidative, cardiovascular and neurodegenerative stress as underlying mechanisms.

View Article and Find Full Text PDF
Article Synopsis
  • The German Lipoprotein Apheresis Registry (GLAR) began in 2012 and collected data from 2,301 patients undergoing lipoprotein apheresis (LA) for high cholesterol and lipoprotein(a) levels over 11 years.
  • The data showed significant reductions in LDL-C (68.8%) and Lp(a) (72.9%) immediately after LA treatment, with substantial decreases in major coronary events (MACE) over the treatment period, particularly an 85% reduction in patients with high Lp(a) levels.
  • Adverse events related to LA were low (around 5%) mainly involving minor issues like puncture problems, with no severe side effects leading to treatment termination.
View Article and Find Full Text PDF

Background And Aims: Familial hypercholesterolemia (FH) is among the most common genetic disorders in primary care. However, only 15% or less of patients are diagnosed, and few achieve the goals for low-density lipoprotein cholesterol (LDL-C). In this analysis of the German Cascade Screening and Registry for High Cholesterol (CaRe High), we examined the status of lipid management, treatment strategies, and LDL-C goal attainment according to the ESC/EAS dyslipidemia guidelines.

View Article and Find Full Text PDF

Lipoprotein apheresis (LA) is usually a last resort in cardiovascular high-risk patients in the context of secondary prevention after lifestyle measures and maximal pharmacotherapy have failed to prevent the occurrence of new atherosclerotic cardiovascular events (ASCVDE) or to achieve the internationally accepted target values for LDL cholesterol (LDL-C). Patients with homozygous familial hypercholesterolemia (hoFH), in whom myocardial infarctions can occur even in children < 10 years of age without adequate therapy, often owe their survival to LA (used here in primary prevention). Severe hypercholesterolemia (HCH) can often be well controlled with modern potent lipid-lowering agents, including PCSK9 approaches, so that the need for LA has decreased here over the years.

View Article and Find Full Text PDF